Joshua J. Neumiller, PharmD, CDE, FASCP Vice-Chair & Associate Professor, Department of Pharmacotherapy Director of Experiential Services Editor-in-Chief, Diabetes Spectrum Washington State University, College of Pharmacy Spokane, WA
Candis M. Morello, PharmD, CDE, FCSHP, FASHP Professor of Clinical Pharmacy Associate Dean for Student Affairs University of California San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences San Diego, CA
1.0 hour (0.10 ceu)
Mobile + Online on RealCME
This activity uses interactive case scenarios to examine the role of the pharmacist in the management of T2D.
. Target Audience
Upon completion of this educational activity, the participant should be able to:
Summarize the current evidence-based practice guidelines for the management of type 2 diabetes (T2D).
Describe barriers to insulin initiation and insulin intensification in patients with T2D.
Review strategies to overcome barriers to successful insulin initiation and intensification.
Describe the current and new insulin therapies and those in late-stage development for the management of T2D.
Joshua J. Neumiller, PharmD, CDE, FASCP, has no relevant affiliations or financial relationships with a commercial interest to disclose.
Candis M. Morello, PharmD, CDE, FCSHP, FASHP, has no relevant affiliations or financial relationships with a commercial interest to disclose.
The planners, managers, and other individuals, not previously disclosed, who are in a position to control the content of this continuing education (CE) activity hereby state that they have no relevant conflicts of interest and no financial relationships or relationships to products or devices during the past 12 months to disclose in relation to this activity. We are committed to providing participants with a quality learning experience and to improve clinical outcomes without promoting the financial interests of a proprietary business. Credit Statements
In support of improving patient care, Rush University Medical Center is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing education for the healthcare team.
Rush University Medical Center designates this knowledge based CPE activity (J0000275-0000-18-003-H01-P) for 1 contact hours for pharmacists.
Credits: 1.0 hour (0.10 ceu)
Published: January 18, 2018
Expires: January 18, 2019
Type of Activity: Knowledge
Estimated time to complete activity: 60 minutes
Fee Information: There is no fee for this educational activity.
HOW TO EARN CREDIT
During the period January 18, 2018 through January 18, 2019, participants must 1) read the learning objectives and faculty disclosures; 2) view the educational activity in its entirety; and 3) complete the post-test and evaluation form directly after the activity within a maximum of 60 days of participating in the activity. If you successfully complete the post-test (score of 70% or higher), your statement of participation will be made available immediately. Commercial Support Statements
This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC.
© 2018 MCM Education. All rights reserved. None of the contents may be reproduced in any form without prior written permission from the publisher.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Rush University Medical Center, MCM Education, Boehringer Ingelheim Pharmaceuticals, Inc., or Lilly USA, LLC. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions, and possible contraindications on dangers in use, (review of any applicable manufacturer's product information) and comparison with recommendations of other authorities.
The author, sponsor, and publisher of this continuing education activity have made all reasonable efforts to ensure that all information contained herein is accurate in accordance with the latest available scientific knowledge at the time of acceptance for publication. However, because information regarding drugs (their administration, dosages, contraindications, adverse reactions, interactions, special warnings, precautions, etc.) is subject to constant change, the reader is advised to check the manufacturer's package insert for information concerning recommended dosages and potential problems and cautions prior to dispensing or administering the drug. Special precautions should be taken when a drug is new, or highly toxic, or is unfamiliar to the dispenser or administrant. This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the U.S. Food and Drug Administration (FDA). Neither the publisher nor sponsor promotes the use of any agent outside of approved labeling. Statements made in this activity have not been evaluated by the FDA. Nutritional products discussed are not intended for the diagnosis, treatment, cure, or prevention of any disease.